D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

D Molecular Therapeutics (NASDAQ:FDMT) achieves FDA RMAT status for 4D-150 as a diabetic macular edema treatment, backed by ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes.

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor ...